{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:47:55Z","timestamp":1791892075835,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1053\/j.semnuclmed.2017.09.003","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T19:47:54Z","timestamp":1505850474000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["PET\/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma"],"prefix":"10.1053","volume":"48","author":[{"given":"Carsten","family":"Kobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0010","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0015","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0020","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0025","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1182\/blood-2008-06-155820","article-title":"Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma","volume":"112","author":"Kobe","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0030","first-page":"181437","article-title":"Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim pet: final results of the international, randomized phase 3 trial hd18 by the German Hodgkin study group","author":"Borchmann","year":"2017","journal-title":"EHA Learning Center"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0035","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2007.07.003","article-title":"Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?","volume":"85","author":"Girinsky","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00108-015-0007-5","article-title":"Current therapeutic strategies for diffuse large B-cell lymphoma","volume":"57","author":"Pfreundschuh","year":"2016","journal-title":"Internist (Berl)"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1629839","article-title":"Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma","volume":"36","author":"Thill","year":"1997","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0060","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0065","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0070","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2010.32.4996","article-title":"[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma","volume":"29","author":"Purz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0075","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0080","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00259-017-3714-4","article-title":"Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained","volume":"44","author":"Hindie","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0085","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjh.14292","article-title":"Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation","volume":"175","author":"Mesguich","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0090","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.2013.53.2507","article-title":"Assessment of tumor size reduction improves outcome prediction of positron emission tomography\/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma","volume":"32","author":"Kobe","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0095","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/10428194.2011.603444","article-title":"Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone","volume":"53","author":"Markova","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1148\/radiol.2441060810","article-title":"Hodgkin disease: diagnostic value of FDG PET\/CT after first-line therapy\u2014is biopsy of FDG-avid lesions still needed?","volume":"244","author":"Schaefer","year":"2007","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1008357126404","article-title":"18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma","volume":"12","author":"de Wit","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2141.2001.03169.x","article-title":"Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?","volume":"115","author":"Spaepen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0120","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V98.10.2930","article-title":"Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease","volume":"98","author":"Weihrauch","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0125","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2006-04-019901","article-title":"Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome","volume":"109","author":"Dann","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0135","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2016.03.005","article-title":"PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis","volume":"101","author":"Sickinger","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"F-18-FDG avidity in lymphoma readdressed: A study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0165","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0360-3016(94)90352-2","article-title":"Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma","volume":"30","author":"Aviles","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0170","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/10428190410001667712","article-title":"Retracted: Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improve outcome","volume":"45","author":"Avil\u00e9s","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0175","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1385\/MO:22:4:383","article-title":"Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy","volume":"22","author":"Aviles","year":"2005","journal-title":"Med Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0180","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3109\/10428194.2013.808008","article-title":"Statement of retraction","volume":"54","author":"Polliack","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0185","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2011.12.067","article-title":"Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging","volume":"84","author":"Dorth","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0190","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0195","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2013.02.007","article-title":"Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy","volume":"86","author":"Shi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0200","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0205","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0210","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","article-title":"Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography","volume":"23","author":"Juweid","year":"2005","journal-title":"J Clin Oncol"},{"issue":"S1","key":"10.1053\/j.semnuclmed.2017.09.003_bib0215","article-title":"Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced-stage diffuse large B-cell lymphoma (DLBCL) treated with RCHOP","volume":"31","author":"Sehn","year":"2013","journal-title":"Hematol Oncol"},{"issue":"suppl","key":"10.1053\/j.semnuclmed.2017.09.003_bib0220","article-title":"Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL","volume":"35","author":"Pfreundschuh","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0225","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3413\/nukmed-0216","article-title":"FDG-PET in Hodgkin lymphoma","volume":"47","author":"Kobe","year":"2008","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0235","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0240","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0245","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.ijrobp.2003.08.033","article-title":"Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group","volume":"58","author":"Eich","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00066-005-1437-0","article-title":"The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel","volume":"181","author":"M\u00fcller","year":"2005","journal-title":"Strahlenther Onkol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0255","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.ijrobp.2007.04.035","volume":"69","author":"Eich","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0260","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/01.coc.0000092701.47861.81","article-title":"The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imaging","volume":"27","author":"Eich","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3413\/Nukmed-0746-15-06","article-title":"Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma","volume":"54","author":"Kobe","year":"2015","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0270","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/annonc\/mdq557","article-title":"Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma\u2014results for dedicated assessment criteria in a blinded dual-centre read","volume":"22","author":"Furth","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0275","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0280","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1200\/JCO.2008.19.7814","article-title":"Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial","volume":"27","author":"Furth","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0285","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.108.057703","article-title":"Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy","volume":"50","author":"Itti","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0290","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00259-014-2715-9","article-title":"qPET\u2014a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma","volume":"41","author":"Hasenclever","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0295","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2967\/jnumed.116.186353","article-title":"Repeatability of SUV in oncologic 18F-FDG PET","volume":"58","author":"Lodge","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0300","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.117.190736","article-title":"Test-retest variability of lesion SUV and lesion SUR in 18F-FDG PET: an analysis of data from two prospective multicenter trials","author":"Hofheinz","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0305","first-page":"608","article-title":"Effect of reconstruction settings and therapy on 18F-FDG PET\/CT blood pool and liver SUV in patients with diffuse large B-cell lymphoma","volume":"58","author":"van den Belt","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.003_bib0310","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00259-015-3165-8","article-title":"Impact of PET\/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis","volume":"43","author":"Kuhnert","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T23:06:05Z","timestamp":1602975965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299817300806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0001299817300806"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}